Trial Profile
A Phase II Study of the mTOR Inhibitor, CCI-779 in Patients With Advanced Non-Small Cell Lung Cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Temsirolimus (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Biomarker; Therapeutic Use
- 17 Dec 2009 Actual end date (Nov 2009) added as reported by ClinicalTrials.gov.
- 17 Dec 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 23 Aug 2005 New trial record.